Investments and investor services
FTSE 100 closes higher despite continued trade worries
The UK's blue-chip benchmark added over 23 points to close at 7,184
Company
Synairgen PLC
LON:SNG
Synairgen PLC is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.
149 stories · page 5 of 8
Archive
US jobs data, ECB policy decision to make for up meagre flow of corporate news in coming week
Asides from the macro news, the Week Ahead also brings the latest quarterly FTSE indexes reshuffle, a strategy update from insurer Aviva, and results from Auto Trader
Archive
Proactive news snapshot: ANGLE, Galantas Gold, SkinBioTherapeutics …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: NetScientific, Capital Drilling, Horizonte Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
RedT Energy Storage shares plunge as it announces strategic review and equity raise
A look at some of the top risers and fallers in London on Thursday.
Synairgen to include more severe COPD patients in phase II SNG001 study
Regulators have given Synairgen the green light to include more severe COPD sufferers in the phase II trial of its SNG001 inhaler following a successful interim safety review
Archive
FTSE 100 closes higher as no deal Brexit fears ease
Footsie closed around 26 points higher at 7,185, while FTSE 250 added around 103 points at 19,283
Synairgen making headway
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
Archive
Proactive news snapshot: Tekcapital, Summit Therapeutics, Widecells …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Mirror and Express newspapers owner Reach rises after increase in adjusted profits
A look at the day's major movers, including IOG, Diurnal, Audioboom, RTC, Baron Oil, United Oil & Gas, Reabold Resources, Andalas Energy, DeepMatter and Fusion Antibodies
Synairgen prelims chart a year of progress
"We look forward to continued progress in 2019," said chairman Simon Shaw.
Investments and investor services
FTSE 100 closes higher but only just as sentiment boosted by trade progress
The UK blue-chip index finished around five points ahead at 7,183
Synairgen’s LOXL2 fibrosis drugs ready for phase II trials
With the receipt of long-term toxicity results, Synairgen and Pharmaxis now have all the data they need to take to potential partners
Archive
Proactive news snapshot: ECSC Group, AFC Energy, Shanta Gold, Iofina PLC …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Hemogenyx, WideCells, Feedback, Synairgen …
A glance at some of the day's highlights from the Proactive Investors newswire
Symphony Environmental surges on UK government plastics ban plans
Some of the main news-driven risers and fallers in London on Monday …
Synairgen kicks off part two of phase II COPD study
The aim of part two is to study the efficacy and safety of the SNG001 inhaler in up to 120 COPD patients with a confirmed respiratory viral infection
FTSE 100 finishes lower as trade worries rear their head again
The UK's premier index of leading shares closed down seven points, or 0.10% at 7,042
Synairgen expands mid-stage COPD study as it raises £2.9mln from investors
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients